Premature Neuroimmune and Redox-Inflammatory Breakdown at the Prodromal Stage in Male and Female Triple-Transgenic Alzheimer’s Disease Mice
Abstract
1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Experimental Design
2.3. Prodromal Behavioral Profile
2.4. Organometrics
2.5. Immune Functions
2.5.1. Collection of Lymphocyte Suspensions
2.5.2. Chemotaxis Assay
2.5.3. Natural Killer (NK) Cytotoxicity Assay
2.5.4. Lymphoproliferation Assay
2.5.5. Cytokine Concentrations in Cultures of Spleen Leukocytes
2.6. Redox-Inflammatory State
2.6.1. Glutathione Peroxidase (GPx) Activity
2.6.2. Glutathione Reductase (GR) Activity
2.6.3. Total Glutathione (GSH) Content
2.6.4. Xanthine Oxidase (XO) Activity
2.7. Plasma Corticosterone
2.8. Statistical Analysis
3. Results
3.1. Prodromal Behavioral State of 4-Month-Old Male and Female 3xTg-AD Mice
3.2. Changes in Physical Condition, Organometrics, and the Endocrine System Are Sex-Dependent and Observable at 4 Months of Age in Male and Female 3xTg-AD Mice
3.3. An Impairment of the Immune Functions Is Presented in 4-Month-Old Female and Male 3xTg-AD Mice
3.4. Oxidative Stress Is Present in the Spleen of 4-Month-Old Female and Male 3xTg-AD Mice
4. Discussion
4.1. Prodromal Behavioral Profile
4.1.1. Characteristics of Early BPSD-like Profile
4.1.2. Specific Sex-Per Genotype-Effects
4.2. Organometrics and Plasma Corticosterone
4.3. Immune Functions
4.3.1. Early Innate and Adaptive Immunity Impairment
4.3.2. Unbalanced Anti-Inflammatory/Proinflammatory Cytokines
4.4. Redox-Inflammatory State
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer Disease. Nat. Rev. Dis. Primers 2021, 7, 33. [Google Scholar] [CrossRef]
- Feigin, V.L.; Vos, T.; Nichols, E.; Owolabi, M.O.; Carroll, W.M.; Dichgans, M.; Deuschl, G.; Parmar, P.; Brainin, M.; Murray, C. The Global Burden of Neurological Disorders: Translating Evidence into Policy. Lancet Neurol. 2020, 19, 255–265. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, D.; Wahlund, L.O.; Westman, E. The Heterogeneity within Alzheimer’s Disease. Aging 2018, 10, 3058. [Google Scholar] [CrossRef]
- Livingston, G.; Huntley, J.; Liu, K.Y.; Costafreda, S.G.; Selbæk, G.; Alladi, S.; Ames, D.; Banerjee, S.; Burns, A.; Brayne, C.; et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024, 404, 572–628. [Google Scholar] [CrossRef]
- Lomi, M.; Geraci, F.; Del Seppia, C.; Dolciotti, C.; Del Carratore, R.; Bongioanni, P. Biomarker profile in peripheral blood cells related to Alzheimer’s disease. Mol. Neurobiol. 2025, 62, 8949–8964. [Google Scholar] [CrossRef] [PubMed]
- Yasumo, F.; Watanabe, A.; Kimura, Y.; Yamauchi, Y.; Ogata, A.; Ikenuma, H.; Abe, J.; Minami, H.; Nihashi, T.; Yokoi, K.; et al. Plasma IL-6 levels as a biomarker for behavioral changes in Alzheimer’s disease. Neuroimmunomodulation 2025, 32, 233–244. [Google Scholar] [CrossRef]
- Malarte, M.L.; Chiotis, K.; Ioannou, K.; Rodriguez-Vieitez, E. Peripheral inflammation is associated with greater neuronal injury and lower episodic memory among late middle-aged adults. J. Neurochem. 2025, 169, e70222. [Google Scholar] [CrossRef]
- De la Fuente, M.; Miquel, J. An update of the oxidation-inflammation theory of aging: The involvement of the immune system in oxi-inflamm-aging. Curr. Pharm. Des. 2009, 15, 3003–3026. [Google Scholar] [CrossRef]
- McManus, R.M. The Role of Immunity in Alzheimer’s Disease. Adv. Biol. 2022, 6, e2101166. [Google Scholar] [CrossRef]
- Long, C.; Fritts, A.; Broadway, J.; Brawman-Mintzer, O.; Mintzer, J. Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer’s Disease. J. Clin. Med. 2025, 14, 331. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M.T.; van der Flier, W.M.; Jessen, F.; Hoozemanns, J.; Thal, D.R.; Boche, D.; Brosseron, F.; Teunissen, C.; Zetterberg, H.; Jacobs, A.H.; et al. Neuroinflammation in Alzheimer disease. Nat. Rev. Immunol. 2025, 25, 321–352. [Google Scholar] [CrossRef] [PubMed]
- Zang, X.; Chen, S.; Zhu, J.; Ma, J.; Zhai, Y. The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases. Front. Aging Neurosci. 2022, 14, 872134. [Google Scholar] [CrossRef]
- Zhang, S.; Gao, Y.; Zhao, Y.; Huang, T.Y.; Zheng, Q.; Wang, X. Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis. Mol. Neurodegener. 2025, 20, 22. [Google Scholar] [CrossRef]
- Vida, C.; Martinez de Toda, I.; Garrido, A.; Carro, E.; Molina, J.A.; De la Fuente, M. Impairment of Several Immune Functions and Redox State in Blood Cells of Alzheimer’s Disease Patients. Relevant Role of Neutrophils in Oxidative Stress. Front. Immunol. 2018, 8, 1974. [Google Scholar] [CrossRef]
- Puzzo, D.; Gulisano, W.; Palmeri, A.; Arancio, O. Rodent Models for Alzheimer’s Disease Drug Discovery. Expert Opin. Drug Discov. 2015, 10, 703–711. [Google Scholar] [CrossRef]
- Sanchez-Varo, R.; Mejias-Ortega, M.; Fernandez-Valenzuela, J.J.; Nuñez-Diaz, C.; Caceres-Palomo, L.; Vegas-Gomez, L.; Sanchez-Mejias, E.; Trujillo-Estrada, L.; Garcia-Leon, J.A.; Moreno-Gonzalez, I.; et al. Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis. Int. J. Mol. Sci. 2022, 23, 5404. [Google Scholar] [CrossRef]
- Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003, 39, 409–421. [Google Scholar] [CrossRef]
- Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; LaFerla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging 2003, 24, 1063–1070. [Google Scholar] [CrossRef] [PubMed]
- Oddo, S.; Caccamo, A.; Green, K.N.; Liang, K.; Tran, L.; Chen, Y.; Leslie, F.M.; LaFerla, F.M. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2005, 102, 3046–3051. [Google Scholar] [CrossRef] [PubMed]
- Oddo, S.; Caccamo, A.; Tran, L.; Lambert, M.P.; Glabe, C.G.; Klein, W.L.; LaFerla, F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer’s disease. A link between Abeta and tau pathology. J. Biol. Chem. 2006, 281, 1599–1604. [Google Scholar] [CrossRef] [PubMed]
- Billings, L.M.; Oddo, S.; Green, K.N.; McGaugh, J.L.; LaFerla, F.M. Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 2005, 45, 675–688. [Google Scholar] [CrossRef] [PubMed]
- Janelsins, M.C.; Mastrangelo, M.A.; Oddo, S.; LaFerla, F.M.; Federoff, H.J.; Bowers, W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J. Neuroinflammation 2005, 2, 23. [Google Scholar] [CrossRef] [PubMed]
- Kitazawa, M.; Oddo, S.; Yamasaki, T.R.; Green, K.N.; LaFerla, F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J. Neurosci. 2005, 25, 8843–8853. [Google Scholar] [CrossRef] [PubMed]
- Sterniczuk, R.; Antle, M.C.; Laferla, F.M.; Dyck, R.H. Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: Part 2. Behavioral and cognitive changes. Brain Res. 2010, 1348, 149–155. [Google Scholar] [CrossRef]
- Belfiore, R.; Rodin, A.; Ferreira, E.; Velazquez, R.; Branca, C.; Caccamo, A.; Oddo, S. Temporal and regional progression of Alzheimer’s disease-like pathology in 3xTg-AD mice. Aging Cell 2019, 18, e12873. [Google Scholar] [CrossRef]
- Giménez-Llort, L.; Blázquez, G.; Cañete, T.; Johansson, B.; Oddo, S.; Tobeña, A.; LaFerla, F.M.; Fernández-Teruel, A. Modeling behavioral and neuronal symptoms of Alzheimer’s disease in mice: A role for intraneuronal amyloid. Neurosci. Biobehav. Rev. 2007, 31, 125–147. [Google Scholar] [CrossRef]
- Muntsant, A.; Castillo-Ruiz, M.D.M.; Giménez-Llort, L. Survival Bias, Non-Lineal Behavioral and Cortico-Limbic Neuropathological Signatures in 3xTg-AD Mice for Alzheimer’s Disease from Premorbid to Advanced Stages and Compared to Normal Aging. Int. J. Mol. Sci. 2023, 24, 13796. [Google Scholar] [CrossRef]
- Giménez-Llort, L.; Torres-Lista, V.; De la Fuente, M. Crosstalk between behavior and immune system during the prodromal stages of Alzheimer’s disease. Curr. Pharm. Des. 2014, 20, 4723–4732. [Google Scholar] [CrossRef]
- Maté, I.; Cruces, J.; Giménez-Llort, L.; De la Fuente, M. Function and redox state of peritoneal leukocytes as preclinical and prodromic markers in a longitudinal study of triple-transgenic mice for Alzheimer’s disease. J. Alzheimer’s Dis. 2015, 43, 213–226. [Google Scholar] [CrossRef]
- Ceprián, N.; Martínez de Toda, I.; Maté, I.; Garrido, A.; Gimenez-Llort, L.; De la Fuente, M. Prodromic Inflammatory-Oxidative Stress in Peritoneal Leukocytes of Triple-Transgenic Mice for Alzheimer’s Disease. Int. J. Mol. Sci. 2024, 25, 6976. [Google Scholar] [CrossRef]
- Giménez-Llort, L.; Arranz, L.; Maté, I.; De la Fuente, M. Gender-specific neuroimmunoendocrine aging in a triple-transgenic 3xTg-AD mouse model for Alzheimer’s disease and its relation with longevity. Neuroimmunomodulation 2008, 15, 331–343. [Google Scholar] [CrossRef]
- St-Amour, I.; Bosoi, C.R.; Paré, I.; Ignatius Arokia Doss, P.M.; Rangachari, M.; Hébert, S.S.; Bazin, R.; Calon, F. Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer’s disease. J. Neuroinflammation 2019, 16, 3. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.H.; Kim, J.; Lee, M.J.; Kim, Y. Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model. Sci. Rep. 2015, 5, 15703. [Google Scholar] [CrossRef]
- Fraile-Ramos, J.; Reig-Vilallonga, J.; Giménez-Llort, L. Glomerular Hypertrophy and Splenic Red Pulp Degeneration Concurrent with Oxidative Stress in 3xTg-AD Mice Model for Alzheimer’s Disease and Its Exacerbation with Sex and Social Isolation. Int. J. Mol. Sci. 2024, 25, 6112. [Google Scholar] [CrossRef]
- Cantone, A.F.; Burgaletto, C.; Di Benedetto, G.; Gaudio, G.; Giallongo, C.; Caltabiano, R.; Broggi, G.; Bellanca, C.M.; Cantarella, G.; Bernardini, R. Rebalancing immune interactions within the brain-spleen axis mitigates neuroinflammation in an aging mouse model of Alzheimer’s disease. J. Neuroimmune Pharmacol. 2025, 20, 15. [Google Scholar] [CrossRef]
- Bai, R.; Guo, J.; Ye, X.Y.; Xie, Y.; Xie, T. Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res. Rev. 2022, 77, 101619. [Google Scholar] [CrossRef] [PubMed]
- Torres-Lista, V.; Parrado-Fernández, C.; Alvarez-Montón, I.; Frontiñán-Rubio, J.; Durán-Prado, M.; Peinado, J.R.; Johansson, B.; Alcaín, F.J.; Giménez-Llort, L. Neophobia, NQO1 and SIRT1 as premorbid and prodromal indicators of AD in 3xTg-AD mice. Behav. Brain Res. 2014, 271, 140–146. [Google Scholar] [CrossRef]
- Shen, L.; Chen, Y.; Yang, A.; Chen, C.; Liao, L.; Li, S.; Ying, M.; Tian, J.; Liu, Q.; Ni, J. Redox Proteomic Profiling of Specifically Carbonylated Proteins in the Serum of Triple Transgenic Alzheimer’s Disease Mice. Int. J. Mol. Sci. 2016, 17, 469. [Google Scholar] [CrossRef] [PubMed]
- De la Fuente, M. Oxidation and inflammation in the immune and nervous systems, a link between aging and anxiety. In Handbook of Immunosenescence; Springer: Berlin/Heidelberg, Germany, 2019; pp. 1–31. [Google Scholar]
- Xie, J.; Van Hoecke, L.; Vandenbroucke, R.E. The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology. Front. Immunol. 2022, 12, 796867. [Google Scholar] [CrossRef]
- Montacute, R.; Foley, K.; Forman, R.; Else, K.J.; Cruickshank, S.M.; Allan, S.M. Enhanced susceptibility of triple transgenic Alzheimer’s disease (3xTg-AD) mice to acute infection. J. Neuroinflammation 2017, 14, 50. [Google Scholar] [CrossRef]
- Munstant, A.; Giménez-Llort, L. Crosstalk of Alzheimer’s disease-phenotype, HPA axis, splenic oxidative stress and frailty in late-stages of dementia, with special concerns on the effects of social isolation: A translational neuroscience approach. Front. Aging Neurosci. 2022, 14, 969381. [Google Scholar] [CrossRef]
- Garrido, A.; Cruces, J.; Ceprián, N.; Corpas, I.; Tresguerres, J.A.; De la Fuente, M. Social environment improves immune function and redox state in several organs from prematurely aging female mice and increases their lifespan. Biogerontology 2019, 20, 49–69. [Google Scholar] [CrossRef]
- Barnes, L.L.; Wilson, R.S.; Bienias, J.L.; Schneider, J.A.; Evans, D.A.; Bennett, D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 2005, 62, 685–691. [Google Scholar] [CrossRef]
- Ferretti, M.; Iulita, M.F.; Cavedo, E.; Chiesa, P.A.; Schumacher Dimech, A.; Santuccione Chadha, A.; Baracchi, F.; Girouard, H.; Misoch, S.; Giacobini, E.; et al. Women’s Brain Project and the Alzheimer Precision Medicine Initiative. Sex differences in Alzheimer disease—The gateway to precision medicine. Nat. Rev. Neurol. 2018, 14, 457–469. [Google Scholar] [CrossRef] [PubMed]
- Suarez, L.M.; Diaz-Del Cerro, E.; Felix, J.; Gonzalez-Sanchez, M.; Ceprian, N.; Guerra-Perez, N.; Novelle, M.G.; Martinez de Toda, I.; De la Fuente, M. Sex differences in neuroimmunoendocrine communication. Involvement on longevity. Mech. Ageing Dev. 2023, 211, 111798. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.T.; Wang, Z.J.; Cai, H.Y.; Yuan, L.; Hu, M.M.; Wu, M.N.; Qi, J.S. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer’s Disease. Neurosci. Bull. 2018, 34, 736–746. [Google Scholar] [CrossRef]
- Kapadia, M.; Mian, M.F.; Michalski, B.; Azam, A.B.; Ma, D.; Salwierz, P.; Christopher, A.; Rosa, E.; Zovkic, I.B.; Forsythe, P. Sex-dependent differences in spontaneous autoimmunity in adult 3xTg-AD mice. J. Alzheimer’s Dis. 2018, 63, 1191–1205. [Google Scholar] [CrossRef] [PubMed]
- Kane, A.E.; Shin, S.; Wong, A.A.; Fertan, E.; Faustova, N.S.; Howlett, S.E.; Brown, R.E. Sex differences in healthspan predict lifespan in the 3xTg-AD mouse model of Alzheimer’s disease. Front. Aging Neurosci. 2018, 10, 172. [Google Scholar] [CrossRef]
- Dennison, J.L.; Ricciardi, N.R.; Lohse, I.; Volmar, C.H.; Wahlestedt, C. Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research. J. Alzheimers Dis. 2021, 80, 41–52. [Google Scholar] [CrossRef]
- Baeta-Corral, R.; De la Fuente, M.; Giménez-Llort, L. Sex-dependent worsening of NMDA-induced responses, anxiety, hypercortisolemia, and organometry of early peripheral immunoendocrine impairment in adult 3xTg-AD mice and their long-lasting ontogenic modulation by neonatal handling. Behav. Brain Res. 2023, 438, 114189. [Google Scholar] [CrossRef]
- Barber, A.J.; Del Genio, C.L.; Swain, A.B.; Pizzi, E.M.; Watson, S.C.; Tapiavala, V.N.; Zanazzi, G.J.; Gaur, A.B. Age, sex and Alzheimer’s disease: A longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients. Alzh Res. Ther. 2024, 16, 134. [Google Scholar] [CrossRef]
- Meziane, H.; Ouagazzal, A.M.; Aubert, L.; Wietrzych, M.; Krezel, W. Estrous cycle effects on behavior of C57BL/6J and BALB/cByJ female mice: Implications for phenotyping strategies. Genes. Brain Behav. 2007, 6, 192–200. [Google Scholar] [CrossRef] [PubMed]
- Lawrence, R.A.; Burk, R.F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem. Biophys. Res. Commun. 1976, 71, 952–958. [Google Scholar] [CrossRef]
- Massey, V.; Williams, C.H., Jr. On the reaction mechanism of yeast glutathione reductase. J. Biol. Chem. 1965, 240, 4470–4480. [Google Scholar] [CrossRef]
- Xu, J.; Wang, B.; Ao, H. Corticosterone effects induced by stress and immunity and inflammation: Mechanisms of communication. Front. Endocrinol. 2025, 16, 1448750. [Google Scholar] [CrossRef]
- Cerejeira, J.; Lagarto, L.; Mukaetova-Ladinska, E.B. Behavioral and psychological symptoms of dementia. Front Neurol. 2012, 3, 73. [Google Scholar] [CrossRef]
- Benaroya-Milshtein, N.; Hollander, N.; Apter, A.; Kukulansky, T.; Raz, N.; Wilf, A.; Yaniv, I.; Pick, C.G. Environmental enrichment in mice decreases anxiety, attenuates stress responses and enhances natural killer cell activity. Eur. J. Neurosci. 2004, 20, 1341–1347. [Google Scholar] [CrossRef]
- Deacon, R.M.J.; Rawlins, J.N.P. T-Maze Alternation in the Rodent. Nat. Protoc. 2006, 1, 7–12. [Google Scholar] [CrossRef]
- Giménez-Llort, L.; Ferré, S.; Martínez, E. Effects of the systemic administration of kainic acid and NMDA on exploratory activity 861 in rats. Pharmacol. Biochem. Behav. 1995, 51, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Clinton, L.K.; Billings, L.M.; Green, K.N.; Caccamo, A.; Ngo, J.; Oddo, S.; McGaugh, J.L.; LaFerla, F.M. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol. Dis. 2007, 28, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Dantzer, R. Neuroimmune interactions: From the brain to the immune system and vice versa. Physiol. Rev. 2017, 98, 477–504. [Google Scholar] [CrossRef]
- Leunig, A.; Gianeselli, M.; Russo, S.J.; Swirski, F.K. Connection and communication between the nervous and immune systems. Nat. Rev. Immunol. 2025, 25, 912–933. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.H.; Dixit, V.D. Metabolic regulation of immunological aging. Nat. Aging 2025, 5, 1425–1440. [Google Scholar] [CrossRef] [PubMed]
- Fukushima, Y.; Ueno, R.; Minato, N.; Hattori, M. Senescence-associates T cells in immunosenescence and disease. Int. Immunol. 2025, 37, 143–152. [Google Scholar] [CrossRef]
- Abbas, A.K.; TRotta, E.; Simeonov, D.R.; Marson, A.; Bluestone, J.A. Revisiting IL-1: Biology and therapeutic prospects. Sci. Immunol. 2018, 3, eaat1482. [Google Scholar] [CrossRef]
- Martinez de Toda, I.; Ceprian, N.; Diaz del Cerro, E.; De la Fuente, M. The role of immune cells in oxi-inflamm-aging. Cells 2021, 10, 2974. [Google Scholar] [CrossRef]
- Poulios, P.; Skampouras, S.; Piperi, C. Deciphering the role of cytokines in aging: Biomarker potential and effective targeting. Mech. Ageing Dev. 2025, 224, 112036. [Google Scholar] [CrossRef] [PubMed]
- Al-Shehri, S.S.; Duley, J.A.; Bansal, N. Xanthine oxidase-lactoperoxidase system and innate immunity: Biochemical actions and physiological roles. Redox Biol. 2020, 34, 101524. [Google Scholar] [CrossRef]
- Fraile-Ramos, J.; Dogoh, F.; Ogiator, M.; Oghagbon, E.K.; Giménez-Llort, L. Cognitive impairment and blood biomarkers of renal dysfunction in high-risk Nigerian population, with special attention to women and diabetes. BMC Neurol. 2025, 25, 158. [Google Scholar] [CrossRef]
- Sonsalla, M.M.; Lamming, D.W. Geroprotective interventions in the 3xTg mouse model of Alzheimer’s disease. GeroScience 2023, 45, 1343–1381. [Google Scholar] [CrossRef]
- Lopes, P.A.; Guil-Guerrero, J.L. Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer’s Disease. Int. J. Mol. Sci. 2025, 26, 5541. [Google Scholar] [CrossRef]
- Dubal, D.B.; Broestl, L.; Worden, K. Sex and gonadal hormones in mouse models of Alzheimer’s disease: What is relevant to the human condition? Biol. Sex Differ. 2012, 3, 24. [Google Scholar] [CrossRef] [PubMed]
- Fertan, E.; Rodrigues, G.J.; Wheeler, R.V.; Goguen, D.; Wong, A.A.; James, H.; Stadnyk, A.; Brown, R.E.; Weaver, I.C.G. Cognitive Decline, Cerebral-Spleen Tryptophan Metabolism, Oxidative Stress, Cytokine Production, and Regulation of the Txnip Gene in a Triple Transgenic Mouse Model of Alzheimer’s Disease. Am. J. Pathol. 2019, 189, 1435–1450. [Google Scholar] [CrossRef] [PubMed]
- Ochi, S.; Iga, J.I.; Funahashi, Y.; Yoshino, Y.; Yamazaki, K.; Kumon, H.; Mori, H.; Ozaki, Y.; Mori, T.; Ueno, S.I. Identifying Blood Transcriptome Biomarkers of Alzheimer’s Disease Using Transgenic Mice. Mol. Neurobiol. 2020, 57, 4941–4951. [Google Scholar] [CrossRef] [PubMed]
- Kapadia, M.; Mian, M.F.; Ma, D.; Hutton, C.P.; Azam, A.; Narkaj, K.; Cao, C.; Brown, B.; Michalski, B.; Morgan, D.; et al. Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer’s disease-associated markers in 3xTg-AD mice. Alzheimer’s Res. Ther. 2021, 13, 30. [Google Scholar] [CrossRef]






| Behavioral Tests | NTg | 3xTg-AD | Factor Analysis G, Genotype S, Sex | ||
|---|---|---|---|---|---|
| Females (n = 11) | Males (n = 9) | Females (n = 8) | Males (n = 10) | ||
| Corner Test | |||||
| Ethogram (Sequence of behavioral events) | |||||
| Vertical activity (latency, s) | 5.72 ± 0.96 | 7.22 ± 2.73 | 9.5 ± 1.2 | 20.7 ± 2.58 **++ | G **, S **, G × S * |
| Locomotor activity | |||||
| Horizontal activity (corners, n) | 13.73 ± 0.98 | 11.89 ± 1.29 | 11.25 ± 2.66 | 8.20 ± 1.42 | n.s., n.s., n.s. |
| Vertical activity (rearings, n) | 6.36 ± 0.47 | 7.22 ± 1.26 | 4.38 ± 1.02 | 2.30 ± 0.63 | G ***, n.s., n.s. |
| Open Field Test | |||||
| Ethogram (Sequence of behavioral events) | |||||
| Initial movement (latency, s) | 1.36 ± 0.28 | 0.33 ± 0.17 | 2.50 ± 0.53 * | 1.10 ± 0.38 | G *, n.s., n.s. |
| Incidence of bizarre behavior (%) | 55.9 ± 12 | 9.69 ± 11 ++ | 76.3 ± 11 * | 100 ± 0 *** ++ | G ***, S **, G × S ** |
| Exit from the center (latency, s) | 6.27 ± 0.63 | 5.66 ± 1.3 | 14.37 ± 3.38 ** | 8.9 ± 1.96 ** | G **, n.s., n.s. |
| Entrance to periphery (latency, s) | 15.36 ± 2.04 | 49.4 ± 16.5 | 48.8 ± 27.6 | 24.2 ± 5.05 | n.s., n.s., G × S ** |
| Vertical activity (latency, s) | 32.18 ± 2.88 | 46.2 ± 10.2 | 72.1 ± 27.1 * | 74.6 ± 21.0 | G *, n.s., n.s. |
| Self-grooming (latency, s) | 142.73 ± 18.16 | 188.33 ± 20.8 | 231.88 ± 22.48 * | 201.3 ± 20.08 | G *, n.s., n.s. |
| Locomotor activity | |||||
| Vertical activity per minute (rearings, n) | r1: 3.82 ± 0.58 r2: 3.36 ± 0.51 r3: 2.73 ± 0.49 r4: 2.09 ± 0.69 r5: 1.64 ± 0.7 | r1: 2.33 ± 0.59 r2: 2.33 ± 0.68 r3: 3 ± 0.71 r4: 3.22 ± 0.56 r5: 3 ± 0.61 | r1: 1.75 ± 0.82 r2: 0.88 ± 0.3 * r3: 1.13 ± 0.4 * r4: 1.13 ± 0.4 + r5: 1.5 ± 0.38 | r1: 2.1 ± 0.63 r2: 1.6 ± 0.59 r3: 2.1 ± 0.5 r4: 2.7 ± 0.71 r5: 2.5 ± 0.85 | G *, n.s., n.s./ G *(r2, r3) S *(r4) n.s. |
| Total vertical activity (rearings, n) | 13.55 ± 1.04 | 13.89 ± 2.57 | 6.37 ± 1.43 * | 11 ± 2.98 | n.s., n.s., n.s. |
| Self-grooming behavior | |||||
| Self-grooming episodes (n) | 1.36 ± 0.20 | 1.33 ± 0.37 | 0.75 ± 0.25 | 1.20 ± 0.25 | n.s., n.s., n.s. |
| Total self-grooming duration (s) | 4.55 ± 0.73 | 4.00 ± 0.85 | 2.50 ± 0.76 | 4.40 ± 0.79 | n.s., n.s., n.s. |
| Emotionality | |||||
| Defecation boli (n) | 4.1 ± 0.55 | 1.56 ± 0.43 ++ | 2 ± 0.57 * | 1.4 ± 0.47 | G *, S **, n.s. |
| Urination (incidence) | 0.27 ± 0.14 | 0 ± 0 | 0.25 ± 0.16 | 0.30 ± 0.15 | n.s., n.s., n.s. |
| T-maze | |||||
| Ethogram (Sequence of behavioral events) | |||||
| Reaching intersection (latency, s) | 11 ± 1.96 | 11.8 ± 2 | 59.6 ± 26.8 ** | 21.5 ±11.4 | G *, n.s., n.s. |
| Exploratory efficiency (time, s) | 44.55 ± 14.3 | 56.0 ± 12.6 | 88.0 ± 27.3 | 36.3 ± 12.0 | n.s., n.s., n.s. |
| Ratio time in the arms (s) | 4.31 ± 0.77 | 4.90 ± 0.72 | 2.86 ± 0.63 * | 2.69 ± 0.37 * | G **, n.s., n.s. |
| Errors (n) | 0.36 ± 0.2 | 0.78 ± 0.28 | 1 ± 0.5 *** ++ | 0.2 ± 0.13 *** +++ | G ***, n.s., G × S * |
| Emotionality | |||||
| Defecation boli (n) | 1.27 ± 0.43 | 0.33 ± 0.17 +++ | 1.37 ± 0.53 | 0.3 ± 0.21 +++ | n.s., S **, n.s. |
| Urination (incidence) | 0.55 ± 0.21 | 0 ± 0 | 0.12 ± 0.12 | 0.10 ± 0.10 | n.s., n.s., n.s. |
| NTg | 3xTg-AD | Factor Analysis G, Genotype S, Sex | |||
|---|---|---|---|---|---|
| Females (n = 11) | Males (n = 9) | Females (n = 8) | Males (n = 10) | ||
| Physical condition | |||||
| Body Weight (g) | 21.7 ± 1.00 | 26.7 ± 0.50 + | 26.3 ± 0.60 * | 34.5 ± 0.90 * + | G ***, S ***, n.s. |
| % WAT in body weight | 1.01 ± 0.06 | 0.80 ± 0.03 | 1.39 ± 0.04 * | 1.22 ± 0.14 * | G ***, S ***, n.s. |
| Peripheral immune system | |||||
| % Thymus in body weight | 0.18 ± 0.06 | 0.12 ± 0.01 | 0.15 ± 0.00 | 0.10 ± 0.00 | G ***, S **, n.s. |
| % Spleen in body weight | 0.38 ± 0.01 | 0.32 ± 0.01 | 0.52 ± 0.02 * | 0.45 ± 0.07 * | G ***, S **, n.s. |
| Endocrine system | |||||
| Adrenal glands (mg) | 8.2 ± 0.2 | 7.40 ± 0.5 | 7.3 ± 0.2 | 9.4 ± 0.6 | n.s., n.s., G × S ** |
| Plasma corticosterone (ng/mL) | 35.5 ± 8.3 | 28.9 ± 7.2 | 43.3 ± 5.7 | 42.6 ± 7.8 | n.s., n.s., n.s. |
| NTg | 3xTg-AD | Factor Analysis G, Genotype Sex | |||
|---|---|---|---|---|---|
| Females (n = 11) | Males (n = 9) | Females (n = 8) | Males (n = 10) | ||
| Spleen leukocyte functions | |||||
| Chemotaxis index | 1604.1 ± 871.75 | 2296.33 ± 747.47 + | 852.82 ± 216.45 * | 558.3 ± 147.71 *** | G ***, n.s., G × S * |
| NK activity (% Lysis) | 31.15 ± 7.49 | 44.11 ± 10.59 + | 20.04 ± 11.16 * | 34.01 ± 8.5 ** | G ***, n.s., G × S * |
| Lymphoproliferation Basal (c.p.m.) | 385.02 ± 100.13 | 847.1 ± 330.06 +++ | 503.07 ± 155.03 | 585.2 ± 120.21 ** | n.s., S ***, G × S ** |
| Response to Con A (%) | 991.04 ± 103.43 | 1012.23 ± 390.07 | 603.29 ± 160.3 ** | 1251.26 ± 280.6 * +++ | n.s., S ***, G × S *** |
| Response to LPS (%) | 863.27 ± 320.31 | 1198.09 ± 205.15 ++ | 305.33 ± 104.5 *** | 1010.11 ± 185.04 +++ | G ***, S ***, G × S * |
| Thymus leukocyte functions | |||||
| Chemotaxis index | 2290.4 ± 983.4 | 2321.4 ± 682.9 | 1366.18 ± 379.1 ** | 720.6 ± 201.4 *** + | G ***, n.s., n.s. |
| NK activity (% Lysis) | 22.19 ± 5.55 | 49.66 ± 7.51 +++ | 19.4 ± 6.25 | 51.22 ± 4.61 +++ | n.s., S ***, n.s. |
| Lymphoproliferation Basal (c.p.m.) | 302.52 ± 50.12 | 468.3 ± 150.55 ++ | 271.63 ± 40.39 | 582.23 ± 160.2 * +++ | n.s., S ***, n.s. |
| Response to Con A (%) | 265.51 ± 31.07 | 191.24 ± 19.8 +++ | 203.12 ± 40.03 *** | 143.1 ± 10.18 *** +++ | G ***, S ***, n.s. |
| Response to LPS (%) | 210.3 ± 60.02 | 172.43 ± 25.33 + | 149.89 ± 20.05 ** | 121.26 ± 15.37 ** | G ***, S **, n.s. |
| NTg | 3xTg-AD | Factor Analysis G, Genotype S, Sex | |||
|---|---|---|---|---|---|
| Females (n = 11) | Males (n = 9) | Females (n = 8) | Males (n = 10) | ||
| Cytokine concentration in response to Concanavaline A | |||||
| IL-2 (pg/mL) | 190 ± 60 | 168 ± 34 | 110 ± 35 *** | 120 ± 30 * | G ***, n.s., n.s. |
| IL-10 (pg/mL) | 24 ± 9 | 130 ± 25 +++ | 8 ± 2 * | 20 ± 6 *** | G ***, S ***, G × S *** |
| IL-1β (pg/mL) | 5 ± 0.7 | 7 ± 2 ++ | 9 ± 2 *** | 4 ± 1 *** +++ | n.s., S **, G × S *** |
| TNF-α (pg/mL) | 12.5 ± 5 | 18 ± 4 + | 24 ± 8 *** | 15 ± 6 ++ | G *, n.s., G × S *** |
| IL-10/TNF-α ratio | 1.6 ± 0.35 | 6.2 ± 1.3 +++ | 0.4 ± 0.05 ** | 1.2 ± 0.7 *** + | G ***, S ***, G × S *** |
| IL-10/IL-2 ratio | 0.13 ± 0.09 | 0.77 ± 0.07 +++ | 0.07 ± 0.04 | 0.16 ± 0.07 *** | G ***, S ***, G × S *** |
| IL-10/IL-1β ratio | 4.8 ± 0.08 | 18.57 ± 1.08 +++ | 0.89 ± 0.05 *** | 5 ± 0.17 *** +++ | G ***, S ***, G × S *** |
| Cytokine concentration in response to Lipopolysaccharide | |||||
| IL-2 (pg/mL) | 33 ± 13 | 37 ± 15 | 13 ± 4 ** | 43 ± 16 +++ | n.s., S ***, G × S ***. |
| IL-10 (pg/mL) | 80 ± 15 | 306 ± 78 +++ | 20 ± 5 ** | 112 ± 40 *** +++ | G ***, S ***, G × S *** |
| IL-1β (pg/mL) | 5 ± 1 | 6 ± 2 | 5 ± 1 | 6 ± 2 | n.s., n.s., n.s. |
| TNF-α (pg/mL) | 18 ± 6 | 18 ± 4 | 17 ± 5 | 16 ± 4 | n.s., n.s., n.s. |
| IL-10/TNF-α ratio | 5.23 ± 0.92 | 14.24 ± 1.95 +++ | 1.34 ± 0.44 *** | 6.30 ± 1.49 *** +++ | G ***, S ***, G × S *** |
| IL-10/IL-2 ratio | 2.42 ± 1.15 | 8.27 ± 3.2 +++ | 1.54 ± 0.75 | 2.6 ± 1.35 *** | G ***, S **, G × S *** |
| IL-10/IL-1β ratio | 16 ± 3.12 | 51 ± 10.02 +++ | 4 ± 1.07 * | 18.67 ± 4.05 *** | G ***, S ***, G × S *** |
| NTg | 3xTg-AD |
Factor Analysis G, Genotype S, Sex | |||
|---|---|---|---|---|---|
| Females (n = 11) | Males (n = 9) | Females (n = 8) | Males (n = 10) | ||
| Glutathione peroxidase activity (mU GPx/mg tissue) | 540 ± 68 | 490 ± 50 + | 450 ± 60 ** | 405 ± 30 ** | G ***, S *, n.s. |
| Glutathione reductase activity (mU GR/mg tissue) | 154 ± 25 | 150 ± 25 | 127 ± 23 * | 112 ± 12 *** | G ***, n.s., n.s. |
| Total reduced glutathione (nmol GSH/mg tissue) | 0.56 ± 0.05 | 0.46 ± 0.05 +++ | 0.38 ± 0.09 *** | 0.36 ± 0.04 *** | G ***, S **, G × S * |
| Xanthine oxidase activity (mU XO/mg tissue) | 6.4 ± 2.1 | 6.1 ± 2 | 8.7 ± 1.15 ** | 9.6 ± 1.7 *** | G ***, n.s., n.s. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Giménez-Llort, L.; Vida, C.; Félix, J.; Quer-Palomas, S.; Manassra, R.; De la Fuente, M. Premature Neuroimmune and Redox-Inflammatory Breakdown at the Prodromal Stage in Male and Female Triple-Transgenic Alzheimer’s Disease Mice. Diseases 2026, 14, 61. https://doi.org/10.3390/diseases14020061
Giménez-Llort L, Vida C, Félix J, Quer-Palomas S, Manassra R, De la Fuente M. Premature Neuroimmune and Redox-Inflammatory Breakdown at the Prodromal Stage in Male and Female Triple-Transgenic Alzheimer’s Disease Mice. Diseases. 2026; 14(2):61. https://doi.org/10.3390/diseases14020061
Chicago/Turabian StyleGiménez-Llort, Lydia, Carmen Vida, Judith Félix, Silvia Quer-Palomas, Rashed Manassra, and Monica De la Fuente. 2026. "Premature Neuroimmune and Redox-Inflammatory Breakdown at the Prodromal Stage in Male and Female Triple-Transgenic Alzheimer’s Disease Mice" Diseases 14, no. 2: 61. https://doi.org/10.3390/diseases14020061
APA StyleGiménez-Llort, L., Vida, C., Félix, J., Quer-Palomas, S., Manassra, R., & De la Fuente, M. (2026). Premature Neuroimmune and Redox-Inflammatory Breakdown at the Prodromal Stage in Male and Female Triple-Transgenic Alzheimer’s Disease Mice. Diseases, 14(2), 61. https://doi.org/10.3390/diseases14020061

